Citations

Clear

590 citation(s) found for "Ho, Ben".

Novel Common Genetic Susceptibility Loci for Colorectal Cancer
Schmit, Stephanie L. , Edlund, Christopher K., Schumacher, Fredrick R. , Harrison, Tabitha A. , Huyghe, Jeroen R. , Qu, Chenxu, Melas, Marilena , Berg, David Van Den , Wang, Hansong, Tring, Stephanie, Plummer, Sarah J. , Alonso, M. Henar , Anton, Kristen , Aragaki, Aaron K. , Arndt, Volker , Barry, Elizabeth L. , Berndt, Sonja I. , Bloomer, Amanda M. , Boehm, Juergen , Brenner, Hermann , Brezina, Stefanie , Buchanan, Daniel D. , Butterbach, Katja, Caan, Bette J. , Carlson, Christopher S. , Castelao, Jose E. , Chang‐Claude, Jenny , Cheng, Ya‐Wen , Chin, Lee Soo, Church, Timothy R. , Correa, Marcia Cruz, Curtis, Keith R. , Duggan, David , Easton, Douglas F. , English, Dallas R. , Fischer, Rocky, Fritsche, Lars G. , Fuchs, Charles S. , Gago-Domínguez, Manuela , Gala, Manish , Gallinger, Steven , Gauderman, W. James, Giovannucci, Edward L. , Gogarten, Stephanie M. , González‐Villalpando, Clicerio, Gonzalez-Villalpando, Elena M., Greenson, Joel K. , Gsur, Andrea , Gunter, Marc J. , Haiman, Christopher A. , Hampe, Jochen , Harlid, Sophia , Harju, John F., Hayes, Richard B. , Hofer, Philipp , Hoffmeister, Michael , Huang, Shu-Chen, Huerta, José María , Hunter, David J., Idos, Gregory , Jackson, Rebecca D. , Jacobs, Eric J. , Jee, Sun Ha , Jenkins, Mark A. , Jia, Wei-Hua , Jiao, Shuo , Joshi, Amit D. , Kolonel, Laurence N. , Kono, Suminori , Krogh, Vittorio , Küehn, Tilman, Küry, Sébastien , LaCroix, Andrea Z. , Laurie, Cecelia , Lejbkowicz, Flavio, Lemire, Mathieu , Lenz, Heinz‐Josef , Levine, David , Li, Li , Lindor, Noralane M. , Liu, Yun-Ru, Lu, Yingchang , Luh, Frank , Ma, Jing , Mancao, Christoph , Manion, Frank J. , Markowitz, Sanford D. , Martín, Vicente , Matsuo, Keitaro , McDonnell, Kevin , McNeil, Caroline E, Murphy, Neil , Offit, Kenneth, Omichessan, Hanane , Cotoré, Jesús Paredes, Pérez‐Mayoral, Julyann, Rennert, Gad , Rennert, Hedy S., Riggs, Bridget M., Schafmayer, Clemens, Sellers, Thomas A. , Seminara, Daniela, Shibata, David , Siegel, Erin M. , Slattery, Martha L. , Stintzing, Sebastian , Taverna, Darin, Thibodeau, Stephen N. , Thomas, Duncan C. , Trichopoulou, Antonia , Duijnhoven, Fränzel J.B. van , Guelpan, Bethany van, Virtamo, Jarmo, Weinstein, Stephanie J. , Win, Aung Ko , Woods, Michael O. , Wu, Anna H. , Wu, Kana , Xiang, Yong-Bing , Zanke, Brent W., Zeng, Yi-Xin , Zhang, Ben , Zubair, Niha, Figueiredo, Jane C. , Lindblom, Annika , Moreno, Vı́ctor , Peters, Ulrike , Conti, David V. , Gruber, Stephen B. , Kühn, Tilman , Buchanan, Daniel D , Win, Aung K , Rennert, Gad , Hoffmeister, Michael , Arndt, Volker , English, Dallas R , Martín, Vicente , Moreno, Victor , Gunter, Marc J , Jenkins, Mark A , Van Den Berg, David J , Harrison, Tabitha A , Matsuo, Keitaro , Kury, Sebastien , Brenner, Hermann , Gago-Dominguez, Manuela , Hampe, Jochen , Murphy, Neil , Hayes, Richard B , Brezina, Stefanie , Conti, David V , Gong, Jian Feng , Albanes, Demetrius , Amos, Christopher I. , Bezieau, Stéphane , Bien, Stephanie A. , Boutron‐Ruault, Marie‐Christine , Campbell, Peter T. , Chan, Andrew T. , Chanock, Stephen Jacob , Cheng, Iona C. , Church, James M. , Coetzee, Gerhard A. , Cotterchio, Michelle , Feskens, Edith J. M. , FitzGerald, Liesel M. , Fortini, Barbara K. , Giles, Graham G. , Grady, William M. , Hopper, John L. , Hudson, Thomas J , Iwasaki, Motoki , Kooperberg, Charles , Li, Christopher I , Lieb, Wolfgang , Lin, Yi , Liu, Yun‐Ru , Loupakis, Fotios , Matsuda, Koichi , McNeil, Caroline E, Milne, Roger L. , Molina, Antonio José , Mukherjee, Bhramar , Newcomb, Polly A. , Palli, Domenico , Pharoah, Paul D.P. , Potter, John D. , Qu, Conghui , Raskin, Leon , Schoen, Robert E. , Severi, Gianluca , Shi, Wei , Shu, Xiao‐Ou , Southey, Melissa C. , Stadler, Zsofia , Stern, Mariana Carla , Tsugane, Shoichiro , Ulrich, Cornelia M. , Vijai, Joseph , White, Emily E. , Wolk, Alicja , Yen, Yun , Kweon, Sun-Seog , Zheng, Wei , Marchand, Loı̈c Le , Casey, Graham , Church, Timothy R , Caan, Bette J , Lindblom, Annika

Mayo Clinic

JNCI: Journal of the National Cancer Institute | April 30, 2018 | Volume: 111 | Issue: 2 | Pages: 146-157

10.1093/jnci/djy099 | PMID 29917119 Get It

Abstract Background Previous genome-wide association studies (GWAS) have identified 42 loci (P < 5 × 10−8) associated with risk of colorectal cancer (CRC). Expanded consortium efforts facilitating the discovery of additional susceptibility loci may capture unexplained familial risk. Methods We conducted a GWAS in European descent CRC cases and control subjects using a discovery–replication design, followed by examination of novel findings in a multiethnic sample (cumulative n = 163 315). In the discovery stage (36 948 case subjects/30 864 control subjects), we identified genetic variants with a minor allele frequency of 1% or greater associated with risk of CRC using logistic regression followed by a fixed-effects inverse variance weighted meta-analysis. All novel independent variants reaching genome-wide statistical significance (two-sided P < 5 × 10−8) were tested for replication in separate European ancestry samples (12 952 case subjects/48 383 control subjects). Next, we examined the generalizability of discovered variants in East Asians, African Americans, and Hispanics (12 085 case subjects/22 083 control subjects). Finally, we examined the contributions of novel risk variants to familial relative risk and examined the prediction capabilities of a polygenic risk score. All statistical tests were two-sided. Results The discovery GWAS identified 11 variants associated with CRC at P < 5 × 10−8, of which nine (at 4q22.2/5p15.33/5p13.1/6p21.31/6p12.1/10q11.23/12q24.21/16q24.1/20q13.13) independently replicated at a P value of less than .05. Multiethnic follow-up supported the generalizability of discovery findings. These results demonstrated a 14.7% increase in familial relative risk explained by common risk alleles from 10.3% (95% confidence interval [CI] = 7.9% to 13.7%; known variants) to 11.9% (95% CI = 9.2% to 15.5%; known and novel variants). A polygenic risk score identified 4.3% of the population at an odds ratio for developing CRC of at least 2.0. Conclusions This study provides insight into the architecture of common genetic variation contributing to CRC etiology and improves risk prediction for individualized screening.
A Randomized Controlled Trial of Preoperative Prophylactic Antibiotics Prior to Percutaneous Nephrolithotomy in a Low Infectious Risk Population: A Report from the EDGE Consortium
Miller, Nicole L. , Abbott, Joel E. , Lange, Dirk , Humphreys, Mitchell R. , Pais, Vernon M., Monga, Manoj , Krambeck, Amy E. , Sur, Roger L. , Chew, Ben H. , Miller, Nicole L

Mayo Clinic

Journal of Urology | April 22, 2018 | Volume: 200 | Issue: 4 | Pages: 801-808

10.1016/j.juro.2018.04.062 | PMID 29684391 Get It

B-Type Natriuretic Peptide Assessment in Patients Undergoing Revascularization for Left Main Coronary Artery Disease
Redfors, Björn , Crowley, Aaron , Ben‐Yehuda, Ori , Lembo, Nicholas , Brown, W. Morris, Banning, Adrian , Sabik, Joseph F. , Stone, Gregg W. , Serruys, Patrick W , Chen, Shmuel , Gersh, Bernard J. , Taggart, David P , Serruys, Patrick W. , Kappetein, A. Pieter , Banning, Adrian

Mayo Clinic

Circulation | April 17, 2018 | Volume: 138 | Issue: 5 | Pages: 469-478

10.1161/circulationaha.118.033631 | PMID 29666071 Get It

Background: Elevated B-type natriuretic peptide (BNP) is reflective of impaired cardiac function and is associated with worse prognosis among patients with coronary artery disease (CAD). We sought to assess the association between baseline BNP, adverse outcomes, and the relative efficacy of percutaneous coronary intervention (PCI) versus coronary artery bypass grafting (CABG) in patients with left main CAD. Methods: The EXCEL trial (Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) randomized patients with left main CAD and low or intermediate SYNTAX scores (Synergy Between PCI With TAXUS and Cardiac Surgery) to PCI with everolimus-eluting stents versus CABG. The primary end point was the composite of all-cause death, myocardial infarction, or stroke. We used multivariable Cox proportional hazards regression to assess the associations between normal versus elevated BNP (≥100 pg/mL), randomized treatment, and the 3-year risk of adverse events. Results: BNP at baseline was elevated in 410 of 1037 (39.5%) patients enrolled in EXCEL. Patients with elevated BNP levels were older and more frequently had additional cardiovascular risk factors and lower left ventricular ejection fraction than those with normal BNP, but had similar SYNTAX scores. Patients with elevated BNP had significantly higher 3-year rates of the primary end point (18.6% versus 11.7%; adjusted hazard ratio [HR], 1.62; 95% confidence interval [CI], 1.16–2.28; P =0.005) and higher mortality (11.5% versus 3.9%; adjusted HR, 2.49; 95% CI, 1.48–4.19; P =0.0006), both from cardiovascular and noncardiovascular causes. In contrast, there were no significant differences in the risks of myocardial infarction, stroke, ischemia-driven revascularization, stent thrombosis, graft occlusion, or major bleeding. A significant interaction ( P interaction =0.03) was present between elevated versus normal BNP and treatment with PCI versus CABG for the adjusted risk of the primary composite end point at 3 years among patients with elevated BNP (adjusted HR for PCI versus CABG, 1.54; 95% CI, 0.96–2.47) versus normal BNP (adjusted HR, 0.74; 95% CI, 0.46–1.20). This interaction was stronger when log(BNP) was modeled as a continuous variable ( P interaction =0.002). Conclusions: In the EXCEL trial, elevated baseline BNP levels in patients with left main CAD undergoing revascularization were independently associated with long-term mortality but not nonfatal adverse ischemic or bleeding events. The relative long-term outcomes after PCI versus CABG for revascularization of left main CAD may be conditioned by the baseline BNP level. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01205776.
Glycine Amidinotransferase (GATM), Renal Fanconi Syndrome, and Kidney Failure
Reichold, Markus, Klootwijk, Enriko, Reinders, Jörg , Milani, Mario , Broeker, Carsten, Laing, Chris, Wiesner, J., Devi, Sulochana, Zhou, Weibin , Schmitt, Roland , Tegtmeier, Ines , Sterner, Christina, Doellerer, Hannes, Renner, Kathrin , Oefner, Peter J. , Dettmer, Katja , Simbuerger, Johann M.B., Stanescu, Horia , Dumitriu, Simona, Patel, Vaksha , Mozere, Monika, Tekman, Mehmet , Jaureguiberry, Graciana, Issler, Naomi, Kesselheim, Anne, Walsh, Stephen B. , Gale, Daniel P. , Howie, Alexander J. , Martins, Joana Raquel , Hall, Andrew M. , Kasgharian, Michael, O’Brien, Kevin , Jain, Mahim , Hammers, Alexander , Charles‐Edwards, Geoff , Choe, Chi‐un , Isbrandt, Dirk , Cebrian-Serrano, Alberto , Sandford, Richard , Konecki, David, Povey, Sue, Lichter‐Konecki, Uta , Gahl, William A. , Warth, Richard , Kleta, Robert , Gale, Daniel P , Davies, Ben , Bockenhauer, Detlef , Warth, Richard , Kleta, Robert , Otto, Edgar A. , Witzgall, Ralph , Iancu, Daniela , Ferreira, Carlos R , Atwal, Paldeep S , Pugh, Christopher William , Unwin, Robert John

Mayo Clinic

Journal of the American Society of Nephrology | April 13, 2018 | Volume: 29 | Issue: 7 | Pages: 1849-1858

10.1681/asn.2017111179 | PMID 29654216 Get It

Background For many patients with kidney failure, the cause and underlying defect remain unknown. Here, we describe a novel mechanism of a genetic order characterized by renal Fanconi syndrome and kidney failure. Methods We clinically and genetically characterized members of five families with autosomal dominant renal Fanconi syndrome and kidney failure. We performed genome-wide linkage analysis, sequencing, and expression studies in kidney biopsy specimens and renal cells along with knockout mouse studies and evaluations of mitochondrial morphology and function. Structural studies examined the effects of recognized mutations. Results The renal disease in these patients resulted from monoallelic mutations in the gene encoding glycine amidinotransferase (GATM), a renal proximal tubular enzyme in the creatine biosynthetic pathway that is otherwise associated with a recessive disorder of creatine deficiency. In silico analysis showed that the particular GATM mutations, identified in 28 members of the five families, create an additional interaction interface within the GATM protein and likely cause the linear aggregation of GATM observed in patient biopsy specimens and cultured proximal tubule cells. GATM aggregates-containing mitochondria were elongated and associated with increased ROS production, activation of the NLRP3 inflammasome, enhanced expression of the profibrotic cytokine IL-18, and increased cell death. Conclusions In this novel genetic disorder, fully penetrant heterozygous missense mutations in GATM trigger intramitochondrial fibrillary deposition of GATM and lead to elongated and abnormal mitochondria. We speculate that this renal proximal tubular mitochondrial pathology initiates a response from the inflammasome, with subsequent development of kidney fibrosis.
The State of US Health, 1990-2016
Collaborators, The US Burden of Disease, Mokdad, Ali H. , Ballestros, Katherine, Echko, Michelle, Glenn, Scott , Olsen, Helen Elizabeth , Mullany, Erin C, Lee, Alex , Khan, Abdur Rahman , Ahmadi, Alireza , Ferrari, Alize J , Kasaeian, Amir , Werdecker, Andrea , Carter, Austin , Zipkin, Ben, Sartorius, Benn , Serdar, Berrin , Sykes, Bryan L. , Troeger, Chris, Fitzmaurice, Christina , Rehm, Colin D. , Santomauro, Damian , Kim, Daniel , Colombara, Danny V. , Schwebel, David C. , Tsoi, Derrick, Nichols, Emma , Oren, Eyal , Charlson, Fiona , Patton, George , Roth, Gregory A. , Kyu, Hmwe Hmwe , Erskine, Holly E , Huang, Hsiang , Martopullo, Ira , Nachega, Jean B. , Sanabria, Juan , Tabb, Karen M. , Krohn, Kristopher J, Cornaby, Leslie, Moses, Mark , Farvid, Maryam S. , Griswold, Max , Criqui, Michael H, Bell, Michelle L. , Nguyen, Minh , Wallin, Mitch, Mirarefin, Mojde, Younis, Mustafa Z , Fullman, Nancy , Liu, Patrick , Briant, Paul Svitil, Gona, Philimon , Havmöller, Rasmus, Kimokoti, Ruth W , Hay, Simon I , Yadgir, Simon , Biryukov, Stan, Vollset, Stein Emil, Alam, Shazia , Frank, Tahvi , Farid, Talha, Miller, Ted R. , Vos, Theo , Bärnighausen, Till , Gebrehiwot, Tsegaye, Yano, Yuichiro , Al‐Aly, Ziyad , Mehari, Alem , Handal, Alexis J. , Kandel, Amit , Anderson, Benjamin O. , Biroscak, Brian J. , Dorsey, E. Ray, Ding, Eric L. , Park, Eun‐Kee , Wagner, Gregory R. , Chen, Honglei , Sunshine, Jacob E. , Khubchandani, Jagdish , Leasher, Janet L , Leung, Janni , Unützer, Jürgen , Cahill, Leah E. , Cooper, Leslie T. , Bräuer, Michael , Breitborde, Nicholas J. K. , Topór-Mądry, Roman , Soneji, Samir , Stranges, Saverio , James, Spencer L , Amrock, Stephen M. , Jayaraman, Sudha , Skirbekk, Vegard , Kinfu, Yohannes , Bhutta, Zulfiqar A , Murray, Christopher J L , Topór‐Mądry, Roman , Bell, Max , Cooper, Leslie T , Collaborators, The US Burden of Disease, Kolte, Dhaval , Nsoesie, Elaine Okanyene , Hosgood, H. Dean, Whiteford, Harvey , Singh, Jasvinder A. , Abbas, Kaja , Ong, Sok King , Degenhardt, Louisa J , Qorbani, Mostafa , Leung, Ricky , Bazargan‐Hejazi, Shahrzad , Vollset, Stein Emil, Mozaffarian, Dariush , Hu, Guoqing , Salomon, Joshua A. , Horino, Masako , Hotez, Peter Jay , Patel, Tejas Kamleshbhai , Akinyemiju, Tomi , Jonas, Jost B , Oren, Eyal

Mayo Clinic

JAMA | April 10, 2018 | Volume: 319 | Issue: 14 | Pages: 1444

10.1001/jama.2018.0158 | PMID 29634829 Get It

Pre-equilibrium competitive library screening for tuning inhibitor association rate and specificity toward serine proteases
Cohen, Itay , Naftaly, Si, Ben‐Zeev, Efrat , Hockla, Alexandra , Radisky, Evette S. , Papo, Niv , Radisky, Evette S

Mayo Clinic

Biochemical Journal | March 14, 2018 | Volume: 475 | Issue: 7 | Pages: 1335-1352

10.1042/bcj20180070 | PMID 29535275 Get It

High structural and sequence similarity within protein families can pose significant challenges to the development of selective inhibitors, especially toward proteolytic enzymes. Such enzymes usually belong to large families of closely similar proteases and may also hydrolyze, with different rates, protein- or peptide-based inhibitors. To address this challenge, we employed a combinatorial yeast surface display library approach complemented with a novel pre-equilibrium, competitive screening strategy for facile assessment of the effects of multiple mutations on inhibitor association rates and binding specificity. As a proof of principle for this combined approach, we utilized this strategy to alter inhibitor/protease association rates and to tailor the selectivity of the amyloid β-protein precursor Kunitz protease inhibitor domain (APPI) for inhibition of the oncogenic protease mesotrypsin, in the presence of three competing serine proteases, anionic trypsin, cationic trypsin and kallikrein-6. We generated a variant, designated APPIP13W/M17G/I18F/F34V, with up to 30-fold greater specificity relative to the parental APPIM17G/I18F/F34V protein, and 6500- to 230 000-fold improved specificity relative to the wild-type APPI protein in the presence of the other proteases tested. A series of molecular docking simulations suggested a mechanism of interaction that supported the biochemical results. These simulations predicted that the selectivity and specificity are affected by the interaction of the mutated APPI residues with nonconserved enzyme residues located in or near the binding site. Our strategy will facilitate a better understanding of the binding landscape of multispecific proteins and will pave the way for design of new drugs and diagnostic tools targeting proteases and other proteins.
Presence of autoimmune disease affects not only risk but also survival in patients with B‐cell non‐Hodgkin lymphoma
Kleinstern, Geffen , Averbuch, Mor, Seir, Rania Abu , Perlman, Riki , Yehuda, Dina Ben , Paltiel, Ora , Abu Seir, Rania

Mayo Clinic

Hematological Oncology | February 23, 2018 | Volume: 36 | Issue: 2 | Pages: 457-462

10.1002/hon.2498 | PMID 29469175 Get It

AbstractAlthough autoimmune diseases (AIDs) are known to predispose to non‐Hodgkin lymphoma (NHL), their association with NHL prognosis has rarely been investigated. We examined associations between autoimmunity and B‐cell NHL onset by comparing AID history (determined by self‐report and medication review and supplemented by chart review where possible) among 435 adult B‐NHL patients in Hadassah‐Hebrew University Medical Center, diagnosed 2009‐2014, and 414 age‐and‐sex frequency‐matched controls. We examined AIDs as a whole, B‐ and T‐cell–mediated AIDs, and autoimmune thyroid diseases. Among cases, we used Kaplan‐Meier and Cox regression models to assess the association of AID with overall survival and relapse‐free survival, adjusting for prognostically important patient and disease characteristics such as Ki67% staining, International Prognostic Index, rituximab treatment, and histological subgroup.Autoimmune diseases were associated with B‐NHL (odds ratio [OR] = 1.95; 95% confidence interval (CI), 1.31‐2.92), especially AIDs mediated by B‐cell activation (OR = 5.20; CI, 1.90‐14.3), which were particularly associated with marginal zone lymphoma (OR = 19.3; CI, 4.59‐80.9). We found that time to relapse for all B‐NHL patients with AIDs was significantly shorter (mean of 49.21 mo [±3.22]) than among patients without AID (mean of 59.74 mo [±1.62]), adjusted hazard ratio [HRadj] = 1.69 (CI, 1.03‐2.79). Specifically, in patients with diffuse large B‐cell lymphoma, of whom 91.8% had received rituximab, a history of B‐cell–mediated AIDs was associated with shorter relapse‐free survival and overall survival, HRadj = 8.34 (CI, 3.01‐23.1) and HRadj = 3.83 (CI, 1.20‐12.3), respectively.Beyond confirming the well‐known association between AIDs and B‐NHL, we found that AID is an adverse prognostic factor in B‐cell lymphoma, associated with a shortened time to relapse, suggesting that there are specific therapeutic challenges in the subgroup of patients suffering from both these diseases. Further work is required to address mechanisms of resistance to standard treatment in the setting of AID‐associated B‐NHL. In the era of immunotherapy, these findings have particular relevance.
High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology
King, Rebecca L. , Jiang, Aixiang , Horn, Heike , Mottok, Anja , Farinha, Pedro , Slack, Graham W. , Ennishi, Daisuke , Schmitz, Norbert , Pfreundschuh, Michael , Nowakowski, Grzegorz S. , Gascoyne, Randy D. , Ott, German , Macon, William R. , Rosenwald, Andreas , Scott, David W. , Staiger, Annette M. , Ben‐Neriah, Susana , Kahl, Brad S. , Connors, Joseph M. , Farinha, Pedro

Mayo Clinic

Blood | February 23, 2018 | Volume: 131 | Issue: 18 | Pages: 2060-2064

10.1182/blood-2017-12-820605 | PMID 29475959 Get It

Key Points HGBL-DH/TH makes up 8% of de novo DLBCL, with HGBL-DH/TH with BCL2 rearrangement being a GCB phenomenon. Restricting FISH testing to tumors with dual protein expression and GCB subtype results in testing <15% of tumors, but missing ∼35% of HGBL-DH/TH.
Converting a broad matrix metalloproteinase family inhibitor into a specific inhibitor of MMP ‐9 and MMP ‐14
Shirian, Jason , Arkadash, Valeria, Cohen, Itay , Sapir, Tamila, Radisky, Evette S. , Papo, Niv , Shifman, Julia M. , Radisky, Evette S

Mayo Clinic

FEBS Letters | February 23, 2018 | Volume: 592 | Issue: 7 | Pages: 1122-1134

10.1002/1873-3468.13016 | PMID 29473954 Get It

MMP ‐14 and MMP ‐9 are two well‐established cancer targets for which no specific clinically relevant inhibitor is available. Using a powerful combination of computational design and yeast surface display technology, we engineered such an inhibitor starting from a nonspecific MMP inhibitor, N‐ TIMP 2. The engineered purified N‐ TIMP 2 variants showed enhanced specificity toward MMP ‐14 and MMP ‐9 relative to a panel of off‐target MMP s. MMP ‐specific N‐ TIMP 2 sequence signatures were obtained that could be understood from the structural perspective of MMP /N‐ TIMP 2 interactions. Our MMP ‐9 inhibitor exhibited 1000‐fold preference for MMP ‐9 vs. MMP ‐14, which is likely to translate into significant differences under physiological conditions. Our results provide new insights regarding evolution of promiscuous proteins and optimization strategies for design of inhibitors with single‐target specificities.
Dusting versus Basketing during Ureteroscopy–Which Technique is More Efficacious? A Prospective Multicenter Trial from the EDGE Research Consortium
Humphreys, Mitchell R. , Shah, Ojas , Monga, Manoj , Krambeck, Amy E. , Sur, Roger L. , Miller, Nicole L. , Knudsen, Bodo E. , Eisner, Brian H. , Matlaga, Brian R., Chang, Yu‐Hui , Chew, Ben H. , Miller, Nicole L

Mayo Clinic

Journal of Urology | December 15, 2017 | Volume: 199 | Issue: 5 | Pages: 1272-1276

10.1016/j.juro.2017.11.126 | PMID 29253579 Get It